Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q3 2019 · 10-Q
Revenue$104.67M$104.67M+51.5% vs Q3 2018 Net Income$2.14M$2.14M+5.9% vs Q3 2018 EPS Diluted$0.02$0.02±0.0% vs Q3 2018 Gross Profit$50,832,000+57.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived$18,634,000+122.3% Free Cash Flowderived$11,318,000+81.6% Margins · derivedGross margin48.6%+1.8 pt vs Q3 2018
Operating margin3.5%−2.2 pt vs Q3 2018
Net margin2.0%−0.9 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 13, 2019 · 44 d after period end